Company intelligence / Profile preview

Il-Yang Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Il-Yang Pharmaceutical has developed several first-in-class drugs in Korea including Noltec® (ilaprazole) for acid-related diseases and Supect® (radotinib) for CML. The company also manufactures WHO-prequalified trivalent influenza vaccine and exports to countries with low vaccine availability. It has a robust R&D pipeline focused on small molecules and biologics such as cytokine-based therapies. Clinical results include multinational approvals for key products.

Therapeutic areas: GastroenterologyInfectious DiseasesOncologyMen's Health
Modalities: Small moleculesinactivated vaccinesprophylactic vaccinesmultivalent vaccinescytokine-based biologics
Industry: Biotech

Drug pipeline

7 assets

quadrivalent influenza vaccine

6 more assets in the full pipeline.

Partnerships

International distribution partners for vaccine export

Beyond the preview

Go deeper on Il-Yang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Il-Yang Pharmaceutical.